Keytruda

FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer

Keytruda (pembrolizumab) and Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in breast, urothelial, gastric and hepatocellular cancers.

GSK discontinues two feladilimab trials in head and neck cancer

The mid-stage study is evaluating feladilimab – GSK3359609 – plus Merck &Co’s Keytruda (pembrolizumab) compared with placebo plus Keytruda for the potential treatment of patients with PD-L1 positive advanced or ... In addition, GSK has also halted

Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients

Although Merck &Co’s rival checkpoint inhibitor Keytruda (pembrolizumab) is dominant in the NSCLC setting, it does not possess similar results in the pre-surgery, neoadjuvant setting. ... With the CheckMate-816 results in hand, Opdivo could gain an

Sanofi pays $160m upfront to acquire Tidal Therapeutics

with Merck &Co’s Keytruda (pembrolizumab) in patients with high-risk melanoma and other cancer types.

Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer

Keytruda plus chemotherapy also significantly improved overall survival in this trial, reducing the risk of death by 27%. ... The first-line approval for Keytruda gives it an advantage over rival checkpoint inhibitor Opdivo (nivolumab) from Bristol Myers

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]